retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide to Weight Loss, Appetite Control & Metabolic Reset Retatrutide: How the Triple Agonist

doi:10.1016/j.xops.2025.100734 24

GLP-1 and GIP control blood glucose levels by stimulating insulin secretion by pancreatic -cells while inhibiting glucagon secretion, increasing pancreatic -cell proliferation, and decreasing their apoptosis [3,4,5,6,7,8]

Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes

In mice, a GLP-1/dexamethasone conjugate circumvented action in the liver and skeletal system to avoid the deleterious effects on glycemic control and bone turnover, respectively, that is evident with systemic dexamethasone action [820]

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

J Med Chem (2007) 50:612632